Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Sergei KutseikinDepartment of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0002-8079-743X
Maria RafiqDepartment of Integrative Computational and Structural Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0001-9118-0788
Prerona BoraDepartment of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0002-3489-6146
Shanshan LiuLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.
Rick A HomanDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA.
Jeffrey T MindreboDepartment of Integrative Computational and Structural Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0003-3063-0620
Matthew HolcombDepartment of Integrative Computational and Structural Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0002-8409-4344
H Michael PetrassiProtego Biopharma, San Diego, CA.
Huang QiuProtego Biopharma, San Diego, CA.
Anastasiya RedkinaProtego Biopharma, San Diego, CA.
Justyna SosnaProtego Biopharma, San Diego, CA.
Thanh-Trang LeeProtego Biopharma, San Diego, CA.
Xiao HuProtego Biopharma, San Diego, CA.
Stefano ForliDepartment of Integrative Computational and Structural Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0002-5964-7111
Christopher G ParkerDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0001-8509-9289
Gabriel C LanderDepartment of Integrative Computational and Structural Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0003-4921-1135
Kivanc BirsoyLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.
Enrique SaezDepartment of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0001-5718-5542
R Luke WisemanDepartment of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA.ORCID 0000-0001-9287-6840
Funding
Scripps Clinical and Translational Science HubUM1TR004407 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI Eric Jeffrey Topol · 2023 to 2026
$24.2M
AutoDock Suite: Next Generation Environment for Drug DesignR01GM069832 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI FORLI, STEFANO · 2004 to 2025
$10.9M
Discovering small molecules activators of stress responsive signalingR01AG046495 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI JEFFERY W KELLY, Rockland Luke Wiseman · 2013 to 2026
$6.0M
Discovering Small Molecule Activators of Stress-Responsive SignalingRF1AG046495 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI KELLY, JEFFERY W, WISEMAN, ROCKLAND LUKE · 2023 to 2025
$2.8M
Pharmacologic targeting of the UPR in obesity-linked liver dysfunctionR01DK137470 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI Enrique Saez, Rockland Luke Wiseman · 2024 to 2026
The endoplasmic reticulum (ER) transporter solute carrier family 33 member 1 (SLC33A1) has emerged as an attractive therapeutic target in etiologically diverse diseases, ranging from lung cancer to neurodegenerative disorders. Yet, no pharmacologic SLC33A1 modulators have been described. Here, we show that the small molecule IXA4, a highly selective activator of the adaptive IRE1/XBP1s signaling arm of the unfolded protein response (UPR), binds to SLC33A1 and inhibits its activity. Genetic depletion of
Indexed as
IRE1/XBP1s signalingpharmacologic UPR activatorsSLC33A1unfolded protein response (UPR)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacological Inhibition of SLC33A1 Promotes Endoplasmic Reticulum Hyperoxidation and Induces Adaptive IRE1/XBP1s Signaling. · full record | OpenQuestion